KYMR News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

KY

Mkt Cap

$8.99B

Volume

323.46K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Kymera's CEO Sold $6 Million in Stock After a 170% RunKymera Therapeutics CEO Nello Mainolfi sold 50,000 shares for $6 million on July 7, 2026, following a 170% stock surge over 12 months. The sale involved exercising options at $2.08 and selling at $119 per share under a pre-scheduled Rule 10b5-1 trading plan. Despite the sale, Mainolfi retains 666,568 shares worth $79.5 million and 90,000 options, indicating continued confidence in the company's pipeline, particularly KT-621 in Phase 2b trials with FDA Fast Track status.The Motley Fool · Jul 12, 2026

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual MeetingKymera Therapeutics announced Phase 1 results for KT-621, a first-in-class oral STAT6 degrader, in healthy Japanese adults at the Japanese Dermatological Association Annual Meeting. The data showed consistent safety and pharmacokinetic/pharmacodynamic profiles with previous studies, demonstrating rapid and sustained STAT6 degradation (≥98% at Day 7). The company has parallel Phase 2b trials ongoing in atopic dermatitis (BROADEN2) and asthma (BREADTH), with data expected by mid-2027 and late 2027, respectively.GlobeNewswire Inc. · Jun 12, 2026

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS CongressesKymera Therapeutics announced preclinical data for KT-579, an oral IRF5 degrader, demonstrating disease-modifying activity in lupus models comparable or superior to approved therapies. The compound showed consistent activity across multiple disease pathways including Type I interferons and pro-inflammatory cytokines. Phase 1 healthy volunteer trial is ongoing with data expected in the second half of 2026, followed by a planned patient proof-of-concept trial in lupus.GlobeNewswire Inc. · Jun 8, 2026

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society CongressesKymera Therapeutics announced presentations of Phase 1b clinical data for KT-621, its first-in-class oral STAT6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses. The data demonstrated deep STAT6 degradation in blood and skin, reductions in Type 2 inflammatory biomarkers, and favorable safety profile. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing with data expected by mid-2027 and late 2027, respectively.GlobeNewswire Inc. · May 15, 2026

Kymera Therapeutics to Participate in Upcoming May Investor ConferencesKymera Therapeutics announced participation in upcoming investor conferences in May 2026 and presented preclinical data for KT-579, its first-in-class oral IRF5 degrader for inflammatory bowel disease, showing activity comparable or superior to approved therapies. The company has Phase 1 data expected in H2 2026 and ongoing Phase 2b trials for KT-621 with results anticipated by mid-to-late 2027.GlobeNewswire Inc. · May 6, 2026

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026Kymera Therapeutics will report Q1 2026 financial results on April 30, 2026. The company announced FDA Fast Track designation for KT-621, a first-in-class oral STAT6 degrader for moderate to severe asthma, with Phase 2b trial data expected in late 2027. Additionally, Gilead Sciences exercised its option to license KT-200, triggering a $45 million milestone payment to Kymera.GlobeNewswire Inc. · Apr 23, 2026

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million ExitHedge fund BVF fully exited its position in Protagonist Therapeutics (PTGX), selling 2.56 million shares worth $170.12 million. Despite the stock rallying 120% over the past year, the fund's exit reflects a disciplined capital rotation strategy following the company's New Drug Application submission for rusfertide in polycythemia vera, marking a shift from clinical-stage risk to regulatory execution risk.The Motley Fool · Feb 25, 2026

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows ConvictionHedge fund BVF invested $52 million in Disc Medicine (IRON) by acquiring 650,000 shares in Q4, demonstrating conviction in the clinical-stage biotech company despite recent FDA setbacks. The investment was made before the FDA's Complete Response Letter in February and a subsequent 20% stock decline. With $791 million in cash runway through 2029, Disc Medicine's investment thesis now hinges on Phase 3 APOLLO trial data expected in Q4 and a potential FDA decision by mid-2027.The Motley Fool · Feb 25, 2026

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology ProgramsKymera Therapeutics announced its 2026 clinical and preclinical milestones, including ongoing Phase 2b trials for KT-621 in atopic dermatitis and asthma with data expected in 2027, initiation of Phase 1 testing for KT-579 in Q1 2026, and advancement of at least one new development candidate toward IND. The company maintains $1.6 billion in cash with runway into 2029.GlobeNewswire Inc. · Jan 13, 2026

Insider Buying: Smart Money Just Spent +$100M on These 3 StocksThree stocks have attracted over $100 million in insider buying from prominent institutional investors: DoorDash (Sequoia Capital), Kenvue (Starboard Value LP), and Kymera Therapeutics (Baker Bros. Advisors). While these purchases signal confidence from sophisticated capital, investors should consider offsetting insider sales and the long-term viability of these bets.Investing.com · Jan 2, 2026

KY

KYMRKymera Therapeutics, Inc. Common Stock

KYMR

Pay with—

Available Balance0.00

Your PositionYou don't own any KYMR yet.

Related Tickers

Earnings